Angiotensin II Receptor Blockers and Angioedema

Introduction to Angioedema Risk

• ACE inhibitors cause angioedema in approximately 0.3% of patients (95% CI: 0.28-0.32) 1
• ARBs like losartan have a much lower incidence of angioedema: 0.11% (95% CI: 0.09-0.13), which is not significantly different from placebo (0.07%; 95% CI: 0.05-0.09) 1

Patient Risk Factors

• ACE inhibitor-induced angioedema occurs in less than 1% of patients but is more frequent in Black patients, according to the American Heart Association 2
• The risk of recurrent angioedema with ARBs after ACE inhibitor-induced angioedema is approximately 2-17%, as noted by the American College of Cardiology 3

Management and Prevention

• For patients with a history of ACE inhibitor-induced angioedema who require RAAS blockade, it is recommended to wait at least 6 weeks after discontinuing the ACE inhibitor before starting an ARB, such as losartan, as recommended by the American College of Cardiology 4, 5, 6
• Alternative antihypertensive classes with no known cross-reactivity include calcium channel blockers, thiazide diuretics, and beta-blockers, as suggested by the American Heart Association 2
• When initiating ARB therapy, close observation during initial dosing, patient education about early signs of angioedema, and instructions to seek immediate medical attention if symptoms develop are necessary 4
• The recommended starting dose of losartan is the lowest effective dose (25-50 mg daily), with cautious titration while monitoring for adverse effects, as recommended by the American College of Cardiology 4
• It is crucial to never rechallenge with another ACE inhibitor, as this is a class effect and potentially life-threatening, according to the American College of Cardiology 3
• Documentation of the angioedema reaction is essential and should be prominently noted in the patient's medical record, as recommended by the American Heart Association 2